View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRubius Therapeutics 将来の成長Future 基準チェック /06現在、 Rubius Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.すべての更新を表示Recent updatesお知らせ • Feb 07Rubius Therapeutics Receives Non-Compliance Letter from NasdaqOn February 6, 2023, Rubius Therapeutics, Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff at least pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. As previously disclosed, on July 27, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market and, in accordance with the Nasdaq Listing Rules, was afforded a 180-calendar day grace period, through January 23, 2023 to regain compliance with the rule. The Company did not regain compliance with minimum bid price requirement by January 23, 2023 and, given the Staff’s separate determination that the Company is a public shell, the Staff did not grant the Company a second grace period to do so.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Langer is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.Seeking Alpha • Aug 09Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03Rubius Therapeutics press release (NASDAQ:RUBY): Q2 GAAP EPS of -$0.49 beats by $0.03. cash, cash equivalents and investments were $140.7 millionお知らせ • Jul 28Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Rubius Therapeutics, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 09, 2022Seeking Alpha • Jun 19Rubius: Poor Data, Punishing Environment, Beaten StockRubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. They have some cash, but it may not last them long enough.Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.Seeking Alpha • Mar 21Rubius Looks Attractive Before AACR Data ReadoutLast year's AACR data saw impressive movement for the stock. This year, expectations are somewhat numbed. However, I still expect some small spike.Price Target Changed • Mar 02Price target increased to US$23.00Up from US$21.33, the current price target is an average from 4 analysts. New target price is 389% above last closing price of US$4.70. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.39 next year compared to a net loss per share of US$2.23 last year.Price Target Changed • Feb 10Price target decreased to US$21.33Down from US$24.50, the current price target is an average from 5 analysts. New target price is 242% above last closing price of US$6.23. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.Price Target Changed • Feb 02Price target decreased to US$23.33Down from US$25.67, the current price target is an average from 5 analysts. New target price is 246% above last closing price of US$6.75. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.Price Target Changed • Dec 24Price target decreased to US$25.67Down from US$28.67, the current price target is an average from 5 analysts. New target price is 134% above last closing price of US$10.98. Stock is up 37% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.分析記事 • Oct 28Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?Today we will run through one way of estimating the intrinsic value of Rubius Therapeutics, Inc. ( NASDAQ:RUBY ) by...Seeking Alpha • Jul 11Our Read On Rubius TherapeuticsToday, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.Breakeven Date Change • May 14Forecast to breakeven in 2025The 4 analysts covering Rubius Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.0m in 2025. Average annual earnings growth of 24% is required to achieve expected profit on schedule.Recent Insider Transactions Derivative • Mar 18Insider exercised options and sold US$313k worth of stockOn the 15th of March, Maiken Keson-Brookes exercised 25k options at a strike price of around US$7.70 and sold these shares for an average price of US$20.24 per share. This trade did not impact their existing holding. As of today, Maiken currently holds no shares directly. Company insiders have collectively sold US$86k more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Mar 10New 90-day high: US$15.01The company is up 95% from its price of US$7.71 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.分析記事 • Feb 25Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...Price Target Changed • Feb 25Price target raised to US$13.25Up from US$11.50, the current price target is an average from 5 analysts. The new target price is 19% above the current share price of US$11.18. As of last close, the stock is up 38% over the past year.Recent Insider Transactions Derivative • Feb 12Executive Chairman notifies of intention to sell stockDavid Epstein intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$14.93, it would amount to US$3.0m. Since March 2020, David has owned 4.82m shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months.Is New 90 Day High Low • Jan 26New 90-day high: US$10.00The company is up 115% from its price of US$4.65 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 27% over the same period.Price Target Changed • Jan 20Price target raised to US$10.29Up from US$9.43, the current price target is an average from 5 analysts. The new target price is 8.2% above the current share price of US$9.51. As of last close, the stock is up 12% over the past year.Is New 90 Day High Low • Jan 08New 90-day high: US$8.83The company is up 62% from its price of US$5.45 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: US$8.73The company is up 72% from its price of US$5.09 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 24New 90-day high: US$5.92The company is up 17% from its price of US$5.05 on 25 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 21New 90-day low: US$4.62The company is down 18% from its price of US$5.63 on 23 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 24New 90-day low: US$4.75The company is down 20% from its price of US$5.93 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Rubius Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:RUBY - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2022N/A-180-155-150N/A9/30/2022N/A-215-161-155N/A6/30/2022N/A-201-159-153N/A3/31/2022N/A-207-159-154N/A12/31/2021N/A-197-149-145N/A9/30/2021N/A-182-142-138N/A6/30/2021N/A-174-136-133N/A3/31/2021N/A-162-130-126N/A12/31/2020N/A-168-133-128N/A9/30/2020N/A-172-144-126N/A6/30/2020N/A-178-153-126N/A3/31/2020N/A-179-167-128N/A12/31/2019N/A-163-151-110N/A9/30/2019N/A-146-132-101N/A6/30/2019N/A-126-121-90N/A3/31/2019N/A-107-89-70N/A12/31/2018N/A-89-73-58N/A9/30/2018N/A-80-60-48N/A6/30/2018N/A-65-38-35N/A3/31/2018N/A-54-33-30N/A12/31/2017N/A-45-24-22N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RUBYの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RUBYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RUBYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RUBYの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RUBYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RUBYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/01/03 03:20終値2023/12/29 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rubius Therapeutics, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Michael SchmidtGuggenheim Securities, LLCAndrew FeinH.C. Wainwright & Co.Michael YeeJefferies LLC2 その他のアナリストを表示
Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.
お知らせ • Feb 07Rubius Therapeutics Receives Non-Compliance Letter from NasdaqOn February 6, 2023, Rubius Therapeutics, Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff at least pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. As previously disclosed, on July 27, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market and, in accordance with the Nasdaq Listing Rules, was afforded a 180-calendar day grace period, through January 23, 2023 to regain compliance with the rule. The Company did not regain compliance with minimum bid price requirement by January 23, 2023 and, given the Staff’s separate determination that the Company is a public shell, the Staff did not grant the Company a second grace period to do so.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Langer is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Sep 13Price target increased to US$7.63Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Aug 10Price target increased to US$10.33Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year.
Seeking Alpha • Aug 09Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03Rubius Therapeutics press release (NASDAQ:RUBY): Q2 GAAP EPS of -$0.49 beats by $0.03. cash, cash equivalents and investments were $140.7 million
お知らせ • Jul 28Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Rubius Therapeutics, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 09, 2022
Seeking Alpha • Jun 19Rubius: Poor Data, Punishing Environment, Beaten StockRubius presented unconvincing data at AACR. The stock is down 80% in just 3 months. They have some cash, but it may not last them long enough.
Price Target Changed • May 12Price target decreased to US$7.60Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 27Price target decreased to US$8.67Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 12Price target decreased to US$9.40Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Apr 09Price target increased to US$23.00Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year.
Seeking Alpha • Mar 21Rubius Looks Attractive Before AACR Data ReadoutLast year's AACR data saw impressive movement for the stock. This year, expectations are somewhat numbed. However, I still expect some small spike.
Price Target Changed • Mar 02Price target increased to US$23.00Up from US$21.33, the current price target is an average from 4 analysts. New target price is 389% above last closing price of US$4.70. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.39 next year compared to a net loss per share of US$2.23 last year.
Price Target Changed • Feb 10Price target decreased to US$21.33Down from US$24.50, the current price target is an average from 5 analysts. New target price is 242% above last closing price of US$6.23. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
Price Target Changed • Feb 02Price target decreased to US$23.33Down from US$25.67, the current price target is an average from 5 analysts. New target price is 246% above last closing price of US$6.75. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
Price Target Changed • Dec 24Price target decreased to US$25.67Down from US$28.67, the current price target is an average from 5 analysts. New target price is 134% above last closing price of US$10.98. Stock is up 37% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year.
分析記事 • Oct 28Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?Today we will run through one way of estimating the intrinsic value of Rubius Therapeutics, Inc. ( NASDAQ:RUBY ) by...
Seeking Alpha • Jul 11Our Read On Rubius TherapeuticsToday, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics. The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs. A full investment analysis follows in the paragraphs below.
Breakeven Date Change • May 14Forecast to breakeven in 2025The 4 analysts covering Rubius Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.0m in 2025. Average annual earnings growth of 24% is required to achieve expected profit on schedule.
Recent Insider Transactions Derivative • Mar 18Insider exercised options and sold US$313k worth of stockOn the 15th of March, Maiken Keson-Brookes exercised 25k options at a strike price of around US$7.70 and sold these shares for an average price of US$20.24 per share. This trade did not impact their existing holding. As of today, Maiken currently holds no shares directly. Company insiders have collectively sold US$86k more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Mar 10New 90-day high: US$15.01The company is up 95% from its price of US$7.71 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
分析記事 • Feb 25Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Price Target Changed • Feb 25Price target raised to US$13.25Up from US$11.50, the current price target is an average from 5 analysts. The new target price is 19% above the current share price of US$11.18. As of last close, the stock is up 38% over the past year.
Recent Insider Transactions Derivative • Feb 12Executive Chairman notifies of intention to sell stockDavid Epstein intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$14.93, it would amount to US$3.0m. Since March 2020, David has owned 4.82m shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months.
Is New 90 Day High Low • Jan 26New 90-day high: US$10.00The company is up 115% from its price of US$4.65 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 27% over the same period.
Price Target Changed • Jan 20Price target raised to US$10.29Up from US$9.43, the current price target is an average from 5 analysts. The new target price is 8.2% above the current share price of US$9.51. As of last close, the stock is up 12% over the past year.
Is New 90 Day High Low • Jan 08New 90-day high: US$8.83The company is up 62% from its price of US$5.45 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: US$8.73The company is up 72% from its price of US$5.09 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 24New 90-day high: US$5.92The company is up 17% from its price of US$5.05 on 25 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 21New 90-day low: US$4.62The company is down 18% from its price of US$5.63 on 23 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 24New 90-day low: US$4.75The company is down 20% from its price of US$5.93 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.